Hemab Therapeutics Holdings, Inc.

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches.

Current securities

1. 3 filingSep 25, 2026
2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 24, 2026
3. 10-Q filingAug 11, 2026
4. Results of Operations and Financial ConditionAug 11, 2026
5. SCHEDULE 13G filingAug 5, 2026